Skip to main content

Table 2 Results of antimicrobial susceptibility testing for clinical isolate E. miricola

From: Elizabethkingia miricola as an opportunistic oral pathogen associated with superinfectious complications in humoral immunodeficiency: a case report

Antimicrobiala

MIC (mg/L)

MIC breakpoint (mg/L)

Interpretation

Susceptible ≤

Resistant >

Cefepime

≥32

4

8

Resistant

Piperacillin

≥128

4

16

Resistant

Piperacillin/Tazobactam

≥128

4

16

Resistant

Ticarcillin/Clavulanic acid

≥128

8

16

Resistant

Ciprofloxacin

≤0.25

0.5

1

Susceptible

Levofloxacin

0.25

1

2

Susceptible

Meropenem

≥16

2

8

Resistant

Gentamicin

8

4

4

Resistant

Amikacin

≥64

8

16

Resistant

Tobramycin

≥16

4

4

Resistant

Colistin

≥16

4

4

Resistant

Antimicrobialb

Inhibition diameter (mm)

Zone diameter breakpoint (mm)

Interpretation

Susceptible ≥

Resistant <

Ceftazidime

6

17

17

Resistant

Cefepime

12

19

19

Resistant

Trimethoprim/Sulfamethoxazole

24

16

16

Susceptible

Amikacin

13

18

15

Resistant

Gentamicin

14

15

15

Resistant

Imipenem

6

20

17

Resistant

Meropenem

6

24

18

Resistant

Levofloxacin

27

20

17

Susceptible

Ciprofloxacin

28

25

22

Susceptible

  1. aAntimicrobial susceptibility testing using Vitek 2 (bioMérieux, Marcy l’Etoile, France), according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines 2016 (http://www.eucast.org). For interpretation, non–species-related (pharmacokinetics/ pharmacodynamics) breakpoints were used except for gentamicin, amikacin, tobramycin and colistin, in which Pseudomonas sp. breakpoints were used
  2. bAntimicrobial susceptibility testing by the disc diffusion method according to 2016 EUCAST guidelines (http://www.eucast.org). For interpretation, non–species-related (pharmacokinetics/ pharmacodynamics) breakpoints were used except for trimethoprim/ sulfamethoxazole, in which Stenotrophomonas maltophilia breakpoints were used, and for gentamicin, amikacin, tobramycin, ciprofloxacin and levofloxacin, in which Pseudomonas sp. breakpoints were used